In conclusion, within this population of HER2‐negative breast cancer patients who were treated with neoadjuvant chemotherapy, a low amount of stroma in pre‐treatment biopsies of the tumor was associated with a higher MP score and pCR rate. This evidence concerns the gene ERBB2 and breast cancer.